Compare Amphastar Pharmaceuticals Inc (AMPH) vs Lufax Holding Ltd (LU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Lufax Holding Ltd — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Lufax Holding Ltd trades at $1.31 (market cap $2.41B). The key difference: Lufax Holding Ltd is far larger — about 2.9× Amphastar Pharmaceuticals Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals.
| AMPH | LU | |
|---|---|---|
Market Cap | $826.08M | $2.41B |
Sector | Health | Technology |
52-Week High | $30.81 | $4.40 |
52-Week Low | $16.87 | $1.23 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
LU trades at $1.34, down 1.47% today, with a neutral technical signal and bearish moving averages. The company reported 2025 revenue of $23.1B but a net loss of $2.1B, with negative profit margins. Analyst consensus is 62% buy, but recent news highlights multiple class-action lawsuits filed against the company, creating significant legal overhangs. Cash flow trends show negative net cash flow of $709M in 2025, driven by heavy investing outflows.
The outlook is mixed: low valuation ratios (P/S 0.34, P/B 0.1) suggest potential upside if profitability improves, but persistent losses, legal risks, and negative cash flow pose substantial downside risks. Investors should weigh cheap valuation against execution challenges and litigation uncertainties in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
